Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 1803-1807

  Robainas, Marianela ^a   Otano, Rafael ^a   Bueno, Stephen ^a   Ait Oudhia, Sihem ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Autophagy; Cancer immunotherapy; Immuno oncology; PD L1; PD1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 METHYLADENINE; AMINO ACID; ARGININE; BAFILOMYCIN; BORTEZOMIB; CHLOROQUINE; CYTOKINE; ERLOTINIB; GEMCITABINE; GLUCOSE; HYDROXYCHLOROQUINE; IMATINIB; MONENSIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TEMOZOLOMIDE; TRYPTOPHAN; WORTMANNIN;

AUTOPHAGY; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL MEMBRANE; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; GLUCOSE METABOLISM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; LYMPH NODE; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; UPREGULATION;

EID: 85016141452     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S132508     Document Type: Review

References (21)

1. Lorin S, Hamai A, Mehrpour M, Codogno P. Autophagy regulation and its role in cancer. Semin Cancer Biol. 2013;23(5):361-379.
2. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5(9):726-734.
3. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402(6762):672-676.
4. Chen N, Karantza-Wadsworth V. Role and regulation of autophagy in cancer. Biochim Biophys Acta. 2009;1793(9):1516-1523.
5. Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17(4):654-666.
6. Brown C. Targeted therapy: an elusive cancer target. Nature. 2016;537(7620):S106-S108.
7. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64(3):1140-1145.
8. Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002;84(1):57-62.
9. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587.
10. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
12. Clark CA, Gupta HB, Sareddy G, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76(23):6964-6974.
13. Parry RV. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543-9553.
14. Moruno F, Pérez-Jiménez E, Knecht E. Regulation of autophagy by glucose in mammalian cells. Cells. 2012;1(3):372-395.
15. Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death Differ. 2008;15(1):70-79.
16. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069-1077.
17. Viry E, Paggetti J, Baginska J, et al. Autophagy: an adaptive metabolic response to stress shaping the antitumor immunity. Biochem Pharmacol. 2014;92(1):31-42.
18. Rao S, Tortola L, Perlot T, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun. 2014;5:3056.
19. Yang S, Imamura Y, Jenkins RW, et al. Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation. Cancer Immunol Res. 2016;4(6):520-530.
20. Starobinets H, Ye J, Broz M, et al. Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. J Clin Invest. 2016;126(12):4417-4429.
21. Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202-216.